Filing Details

Accession Number:
0001209191-21-001724
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-01-05 21:03:46
Reporting Period:
2021-01-04
Accepted Time:
2021-01-05 21:03:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1595893 Turning Point Therapeutics Inc. TPTX Pharmaceutical Preparations (2834) 463826166
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1654482 Mohammad Hirmand C/O Turning Point Therapeutics, Inc.
10628 Science Center Drive, Ste. 200
San Diego CA 92121
Evp And Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-01-04 8,747 $54.73 9,331 No 4 M Direct
Common Stock Disposition 2021-01-04 300 $122.44 9,031 No 4 S Direct
Common Stock Disposition 2021-01-04 8,747 $120.42 284 No 4 S Direct
Common Stock Acquisiton 2021-01-05 1,253 $54.73 1,537 No 4 M Direct
Common Stock Disposition 2021-01-05 1,253 $120.00 284 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2021-01-04 8,747 $0.00 8,747 $54.73
Common Stock Stock Option (right to buy) Disposition 2021-01-05 1,253 $0.00 1,253 $54.73
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
170,445 2029-12-01 No 4 M Direct
169,192 2029-12-01 No 4 M Direct
Footnotes
  1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020.
  2. The Reporting Person acquired 300 shares on June 12, 2020 pursuant to the Issuer's Employee Stock Purchase Plan (the "ESPP") and 284 shares on December 10, 2020 pursuant the ESPP.
  3. The weighted average sale price for the transaction reported was $120.42, and the range of prices were between $120.00 and $121.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  4. 25% of the shares vest on December 2, 2020 and 1/48th of the shares vest monthly thereafter over the next three years.